A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan | MicrobiomeTrials
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-12-01Est. Completion: 2030-12
Enrollment target: 100 participants
Locations
Beverly Hills Cancer Center /ID# 275465, Beverly Hills, California, United States
City of Hope National Medical Center /ID# 275613, Duarte, California, United States
Valkyrie Clinical Trials /ID# 275547, Los Angeles, California, United States
Yale University School of Medicine /ID# 275978, New Haven, Connecticut, United States
Florida Cancer Specialists - North /ID# 277137, St. Petersburg, Florida, United States
Northwestern University Feinberg School of Medicine /ID# 276436, Chicago, Illinois, United States
University of Chicago Medical Center /ID# 275342, Chicago, Illinois, United States
START Midwest /ID# 276603, Grand Rapids, Michigan, United States
Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 275999, New York, New York, United States
Duke Cancer Institute /ID# 275604, Durham, North Carolina, United States
SCRI Oncology Partners /ID# 275686, Nashville, Tennessee, United States
Dell Seton Medical Center /ID# 276474, Austin, Texas, United States
University of Texas - Southwestern Medical Center /ID# 276053, Dallas, Texas, United States
The University of Texas MD Anderson Cancer Center /ID# 275663, Houston, Texas, United States
Other microbiome trials you might be interested in
Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET AmplificationLung Adenocarcinoma Stage IIIB/IV
This study looked at how effective the study drug (tepotinib) was at stopping the growth and spread of lung cancer. This…